Cancer is one of the main causes of death around the world (
1). In recent years, there have been many studies conducted to investigate the application of nanomaterials in cancer diagnosis and treatment. Nanomaterials are small objects with at least one dimension of 1 - 100 nm (
2). Nanomaterials can damage cell membranes and DNA and lead to cell death through reactive oxygen species (ROS) production; thus, they can destroy cancer cells (
1,
3). Mesoporous silica nanoparticles (MSN) known as inorganic nanoparticles (
4) are non-metal (
5), solid, and highly porous oxides (
6). These nanoparticles are used broadly in engineering, industry, biomedical applications, cosmetics, and FDA-approved food additives (
7). MSNs are plentiful in nature, confirmed as generally recognized as safe (GRAS) by the FDA (
8). One of the main advantages of MSN is explicitly low toxicity profile in vivo. Although clinical translation remains challenging, MSN is a promising tool for innovative, efficient, and safe cancer therapies (
9-
11). The fabrication of MSNs is simple and cost-effective (
4). MSNs have the following desirable features as nano-vehicles: low toxicity, large pore volume, large surface area, ease of size-controlling, high synthesis scalability (
12), low immunogenicity, and ability to be endocytosed by cells (
13), tailorable pore sizes, and dual-function surfaces (exterior and interior) (
14). MSNs as drug carriers have been used for cancer treatment on small creatures showing good results (
15). One of the most important features of MSNs as carriers is controlled drug release (
16,
17). One of the problems in cancer therapy is the resistance of cancer cells to the drugs that is called cancer multi-drug resistance (MDR). MSNs can deliver siRNA and lead to a reduction in drug resistance of cancer cells (
18). Increasing the efficiency and reducing the side effects of anticancer drugs are the characteristics of MSNs (
19,
20). MSNs can be used as drug delivery vehicles because of their biocompatibility, the absence of systemic toxicity, and specific targeting of tumor tissues through binding to antibodies or ligands (
21-
23).
HpD is a complex mixture of monomeric and aggregated porphyrins with a photosensitizing ability. By systemic administration, HpD accumulates in cancer cells; when activated with laser light at 630 nm (in presence of oxygen), it produces singlet oxygen and other reactive oxygen radicals that result in local radical-mediated cancer cell death (
24).
The aim of this study was to evaluate the effects of HpD-loaded MSN on the cell proliferation and invasion in human breast adenocarcinoma cancer cell line, MCF7 (
25). The antioxidant effects of this structure were also studied.